Nov 08, 2024 8:01am EST Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
Oct 31, 2024 9:00am EDT Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
Sep 04, 2024 8:00am EDT Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 08, 2024 4:19pm EDT Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jul 09, 2024 8:01am EDT Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
May 15, 2024 8:01am EDT Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
May 10, 2024 8:01am EDT Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
May 09, 2024 4:08pm EDT Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Apr 02, 2024 8:01am EDT Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
Mar 14, 2024 4:09pm EDT Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
